Bristol-Myers Squibb: Carcinoma, Non-Small-Cell Lung trials

The registry lists 119 Carcinoma, Non-Small-Cell Lung studies with Bristol-Myers Squibb as lead sponsor. 20 are open to participants now and 43 have results posted.

Early Phase 1 1Phase 1 35Phase 2 48Phase 3 27Phase 4 2No phase 22(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung CancerCompletedNCT01545947Phase 1
• A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT01478685Phase 1
• Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseCompletedNCT01167244Phase 2
• Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01024062Phase 2
• A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung CancerTerminatedNCT00975767Phase 1
• Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung CancerTerminatedNCT00850577Phase 2
• A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCCompletedNCT00743938Phase 2
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
• Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00651508Phase 2
• Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer TumorsTerminatedNCT00511576Phase 1
• A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)TerminatedNCT00461110Phase 1
• Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)TerminatedNCT00359450Phase 2
• An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With CarboplatinCompletedNCT00274443Phase 2
• Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung CancerTerminatedNCT00179699Phase 1
• A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung CancerCompletedNCT00179686Phase 2
• Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung CancerCompletedNCT00103831Phase 1/2
• Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung CancerTerminatedNCT00099879Phase 2
• Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00073723Phase 1/2
• Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung CancerCompletedNCT00035152Phase 3